Efficacy of Drospirenone-Containing Hormone Replacement Therapy to Reduce Vasomotor Symptoms of Menopause

被引:0
作者
Brown, Dana A. [1 ]
Henneman, Amy [1 ]
Desai, Darshana N. [1 ]
机构
[1] Palm Beach Atlantic Univ, Lloyd L Gregory Sch Pharm, 901 S Flagler Dr,POB 24708, W Palm Beach, FL 33416 USA
来源
PHARMACY | 2013年 / 1卷 / 02期
关键词
drospirenone; estradiol-drospirenone combination; hormone replacement therapy; menopause; postmenopause; premenopause; climacteric; and vasomotor system;
D O I
10.3390/pharmacy1020193
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hormone replacement therapy has been proven efficacious for controlling vasomotor symptoms such as hot flushes associated with menopause. Drospirenone is a progestin with antiandrogenic and antimineralocorticoid activity that may be used in combination with estrogen to control hot flushes and offers the potential benefit of minimizing breast tenderness, blood pressure elevations and weight gain. Six clinical trials were reviewed. Of these, four trials explicitly listed hot flushes as a primary outcome. Efficacy with regards to hot flushes was found to range from modest to large (i.e., 37.5% to 94.6%), and four of the studies utilized diary cards to assess hot flushes. Results from these studies must be interpreted cautiously as quite a few limitations existed such as small population sizes involving specific ethnic groups, lack of p values with regards to baseline characteristics lending question to homogeneity, and inclusion of mostly healthy participants. Additionally, while the studies were long enough to see an effect, the long term effects of drospirenone-containing hormone replacement therapy (HRT) is unknown. The available data supports the use of drospirenone-containing HRT for the treatment of hot flushes associated with menopause.
引用
收藏
页码:193 / 203
页数:11
相关论文
共 14 条
  • [1] Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial
    Archer, DF
    Thorneycroft, IH
    Foegh, M
    Hanes, V
    Glant, MD
    Bitterman, P
    Kempson, RL
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2005, 12 (06): : 716 - 727
  • [2] Carranza-Lira S, 2009, CLIN INTERV AGING, V4, P59
  • [3] Chaikittisilpa Sukanya, 2011, Journal of the Medical Association of Thailand, V94, P1019
  • [4] The safety of a drospirenone-containing oral contraceptive:: final results from the European Active Surveillance study on Oral Contraceptives based on 142,475 women-years of observation
    Dinger, Juergen C.
    Heinemann, Lothar A. J.
    Kuehl-Habich, Doerthe
    [J]. CONTRACEPTION, 2007, 75 (05) : 344 - 354
  • [5] Clinical and metabolic effects of drospirenone-estradiol in menopausal women: a prospective study
    Gambacciani, M.
    Rosano, G.
    Cappagli, B.
    Pepe, A.
    Vitale, C.
    Genazzani, A. R.
    [J]. CLIMACTERIC, 2011, 14 (01) : 18 - 24
  • [6] Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: A double-blind, randomized, placebo-controlled, multicenter study
    Lee, B. S.
    Kang, B. M.
    Yoon, B. K.
    Choi, H.
    Park, H. M.
    Kim, J. G.
    [J]. MATURITAS, 2007, 57 (04) : 361 - 369
  • [7] Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9
    Lidegaard, Ojvind
    Nielsen, Lars Hougaard
    Skovlund, Charlotte Wessel
    Skjeldestad, Finn Egil
    Lokkegaard, Ellen
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2011, 343 : d6423
  • [8] Estradiol 1 mg and drospirenone 2 mg as hormone replacement therapy in postmenopausal Chinese women
    Lin, S-Q.
    Sun, L-Z.
    Lin, J-F.
    Yang, X.
    Zhang, L-J.
    Qiao, J.
    Wang, Z-H.
    Xu, Y-X.
    Xiong, Z-A.
    Zhou, Y-Z.
    Wang, M-L.
    Zhu, J.
    Chen, S-R.
    Su, H.
    Yang, C-S.
    Wang, S-H.
    Zhang, Y-Z.
    Dong, X-J.
    [J]. CLIMACTERIC, 2011, 14 (04) : 472 - 481
  • [9] Drospirenone, a progestogen with antimineralocorticoid properties: a short review
    Oelkers, W
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2004, 217 (1-2) : 255 - 261
  • [10] IMS updated recommendations on postmenopausal hormone therapy
    Pines, Amos
    Sturdee, David W.
    Birkhauser, Martin H.
    Schneider, Hermann P. G.
    Gambacciani, Marco
    Panay, Nick
    [J]. CLIMACTERIC, 2007, 10 (03) : 181 - 194